Venture Fund Member Profile
|
 |
 |
Burrill & Company is a life sciences merchant bank focused exclusively on companies involved in biotechnology, pharmaceuticals, diagnostics, devices, human healthcare and related medical technologies, nutraceuticals and wellness, agricultural biotechnology, and industrial biotechnology (biomaterials/bioprocesses) with over $500 million under management. Burrill's technical and venture investing competence spans the entire spectrum of life sciences.
 |
John Hamer
Managing Director
Burrill & Company |
John joined Burrill & Company in November 2003 as Entrepreneur-In-Residence. John helped to build Paradigm Genetics Inc. a publicly-traded biotechnology company in Research Triangle Park, North Carolina from its beginning in 1998 serving in various capacities as Director of Microbial Research, Vice President of Research, Chief Scientific Officer, Vice President for Business Development and Interim President and CEO. John received his Ph.D. in Microbiology from the University of California, Davis in 1987 and was a visiting scientist at Dupont's Central Research and Development from 1987 to 1989. He served on the faculty of Purdue University where he held the positions of Assistant Professor ('89-'90), Associate Professor ('92-'98), Professor ('98-'00) and Adjunct Professor of Microbiology and Immunology at Indiana University/Purdue University Medical School. He currently holds an honorary position as Adjunct Professor of Biological Sciences. John has received numerous grants and awards of distinction throughout his career and has served on numerous scientific review and biotechnology advisory boards.
Representative Investments
 |
e-Markets B2B transaction and contract management systems, web service and system to systems integration specialists, enterprise software developer and provider to the agricultural and food industry. Their applications remove barriers between buyers and sellers, enable information sharing across the agri-food chain and streamline back office processes. This results in customers achieving a significant return on investment created by the efficiencies of the integration of information into their back office, improved sales efficiency, improved supply chain coordination, and better decision making by all parties sharing the system. |
 |
Agilix Corporation Agilix Corporation develops high-value solutions to overcome key bottlenecks in the areas of gene and protein analyses for drug discovery and development. These solutions are provided through the Company’s proprietary technologies: GenCompass™ and i-PROT™. The GenCompass™ platform employs a universal chip for whole genome expression profiling of known and unknown genes across the spectrum of pharmaceutically relevant organisms. The GenCompass array technology does not depend on prior sequencing, thereby increasing the scope and efficiency of gene expression analyses. The i-PROT™ platform allows multiplexed, quantitative protein profiling with unparalleled signal to noise ratio to enhance biomarker discovery, target validation and characterization, and ADME toxicology information. |
 |
Morphotek Morphotek is a biotechnology company that develops and optimizes biotherapeutics through the enhanced evolution of virtually any cell line or organism. Through its patented platform technology, morphogenics, the company can alter the genome within the living cell, generating improved, genetically diverse lines with new biological characteristics resulting in cell lines with improved antibody or protein therapeutic production, biotherapeutics with improved affinity or efficacy, or cell lines useful in drug discovery or industrial applications. This unique technology eliminates the time-consuming need for gene isolation, in vitro structural alterations, and molecular validation. The result is products that are both efficacious and cost-effective. Morphotek applies its technology with corporate partners as well as employing its platform to develop an internal pipeline of therapeutic antibody products. |
 |
Targacept Targacept is an emerging central nervous system-focused biopharmaceutical company engaged in the design, discovery and development of a new class of drugs to treat a broad spectrum of diseases and disorders, including, among others, cognitive impairment in the elderly, Alzheimer's disease, attention deficit hyperactivity disorder, ulcerative colitis and pain. Supported by an extensive patent estate, the company’s product development pipeline consists of a number of clinical and preclinical product candidates that are designed to selectively modulate a class of molecular targets known as neuronal nicotinic acetylcholine receptors (NNRs) that are key regulators of CNS activity. As a leader in NNR research, Targacept's expertise, together with its proprietary databases and sophisticated computer-based molecular design technologies that it refers to collectively as Pentad, facilitate highly-targeted drug design and development. |
============================================
About FundingPost
For over Twelve Years FundingPost has worked with thousands
of Angel and Venture Capital Investors. We believe that it is
important to reach investors in every medium possible -
both online and offline. We have been directly responsible for
tons of success stories and Millions and Millions of dollars raised.
We look forward to introducing your company to the leading Venture and Angel Investors nationwide.
============================================
|
| Venture Fund Member Profile |
|
Bookmark to del.icio.us
Tweet this Profile
